Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

OBJECTIVE: To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis. METHODS: Data were integrated from seven trials (NCT01668641, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700, NCT03025308)....

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L, Tanaka, Yoshiya, Takeuchi, Tsutomu, Kivitz, Alan, Matzkies, Franziska, Genovese, Mark C, Jiang, Deyuan, Chen, Kun, Bartok, Beatrix, Jahreis, Angelika, Besuyen, Robin, Burmester, Gerd R, Gottenberg, Jacques-Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762003/
https://www.ncbi.nlm.nih.gov/pubmed/34740884
http://dx.doi.org/10.1136/annrheumdis-2021-221051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762003/
https://www.ncbi.nlm.nih.gov/pubmed/34740884
http://dx.doi.org/10.1136/annrheumdis-2021-221051

Ejemplares similares